GlassScriptPhysician profile
Sarvesh Rajan
NPI 1912915554
$5,038.29
in general payments reported to CMS, 2019-2025
45 companies · $1,102 in 2025
The $1,102 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $186 · 2021: $362 · 2022: $717 · 2023: $945 · 2024: $1,039 · 2025: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,684 · Education: $226 · Long Term Medical Supply Or Device Loan: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,684.48 |
| Education | $225.89 |
| Long Term Medical Supply Or Device Loan | $174.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $929.59 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $495.28 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $319.02 | 2022-2025 | Freestyle Copilot, Proclaim, Freestyle Libre 3 |
| Amgen INC. | $298.55 | 2019-2025 | Evenity, Tepezza, Prolia |
| Sanofi-Aventis U.S. LLC | $256.15 | 2019-2025 | |
| Madrigal Pharmaceuticals | $222.06 | 2024-2025 | Rezdiffra, Resmetirom |
| Bayer Healthcare Pharmaceuticals INC. | $202.71 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $199.11 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Dexcom, INC. | $189.05 | 2021-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $175.28 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.05 | 2021-2025 | Jardiance |
| Insulet Corporation | $159.32 | 2019-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $150.63 | 2019-2025 | Lokelma |
| Tandem Diabetes Care, INC. | $99.07 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Antares Pharma, INC. | $85.78 | 2024-2025 | Xyosted |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $78.25 | 2023-2025 | Strensiq |
| Ultragenyx Pharmaceutical INC. | $66.15 | 2022-2024 | Crysvita, Crysvita |
| Neurocrine Biosciences, INC. | $64.45 | 2024-2025 | |
| Corcept Therapeutics | $63.86 | 2019-2023 | Korlym |
| Ibsa Pharma INC. | $59.81 | 2022-2024 | Licart, Tirosint, Tirosint |
| Merck Sharp & Dohme LLC | $55.69 | 2019-2022 | |
| Medtronic Minimed, INC. | $51.21 | 2019-2020 | |
| Shire North American Group INC | $46.74 | 2019 | |
| Kyowa Kirin, INC. | $44.30 | 2023-2025 | Crysvita |
| Amneal Pharmaceuticals LLC | $41.03 | 2025 | Unithroid |
| Novartis Pharmaceuticals Corporation | $40.19 | 2024-2025 | |
| Horizon Therapeutics Plc | $38.55 | 2022-2023 | Tepezza |
| Beta Bionics, INC. | $38.05 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ascendis Pharma Endocrinology INC | $37.88 | 2025 | Yorvipath |
| Medtronic, INC. | $37.52 | 2023-2024 | Inpen Smart Insulin Delivery System |
| Janssen Pharmaceuticals, INC | $37.32 | 2019 | |
| Recordati_rare_diseases_inc. | $35.03 | 2021-2025 | Isturisa |
| Amarin Pharma, INC. | $28.25 | 2019-2022 | |
| Chiesi USA, INC. | $26.15 | 2024 | Myalept |
| Sequel Med Tech, LLC | $24.79 | 2025 | Twiist |
| Regeneron Healthcare Solutions, INC. | $24.12 | 2019 | |
| Amryt Pharma Holdings LTD | $21.46 | 2021 | |
| Alvogen INC | $20.90 | 2023 | Teriparatide |
| Rhythm Pharmaceuticals, INC. | $20.27 | 2025 | Imcivree |
| Vapotherm INC | $16.16 | 2022 | |
| Inspire Medical Systems, INC. | $16.16 | 2025 | Inspire |
| Glaxosmithkline, LLC. | $16.02 | 2023 | Arexvy, Shingrix |
| Pfizer INC. | $13.65 | 2021 | |
| Currax Pharmaceuticals LLC | $13.34 | 2024 | Contrave, Onzetra Xsail |
| Eisai INC. | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarvesh Rajan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.